US 11,744,867 B2
Modulation of microbial synthesis of 4-ethylphenol and 4-ethylphenyl sulfate in behavior and disease
Brittany D. Needham, Pasadena, CA (US); Sarkis K. Mazmanian, Pasadena, CA (US); Gil Sharon, Pasadena, CA (US); Masanori Funabashi, San Francisco, CA (US); Michael A. Fischbach, San Francisco, CA (US); Elaine Y. Hsiao, Pasadena, CA (US); and Paul H. Patterson, Pasadena, CA (US)
Assigned to California Institute of Technology, Pasadena, CA (US); and The Regents of the University of California, Oakland, CA (US)
Filed by California Institute of Technology, Pasadena, CA (US); and The Regents of the University of California, Oakland, CA (US)
Filed on Jul. 23, 2021, as Appl. No. 17/443,273.
Application 17/443,273 is a continuation of application No. 16/485,403, granted, now 11,224,624, previously published as PCT/US2018/018069, filed on Feb. 13, 2018.
Claims priority of provisional application 62/458,716, filed on Feb. 14, 2017.
Prior Publication US 2022/0096575 A1, Mar. 31, 2022
Int. Cl. A61K 35/741 (2015.01); A61K 35/747 (2015.01); A23L 33/135 (2016.01); A61P 25/22 (2006.01); A61K 9/00 (2006.01)
CPC A61K 35/747 (2013.01) [A23L 33/135 (2016.08); A61K 9/0031 (2013.01); A61K 9/0053 (2013.01); A61P 25/22 (2018.01)] 17 Claims
OG exemplary drawing
 
1. A composition comprising a genetically engineered Bacteroides ovatus comprising a loss-of-function mutation in a gene encoding tyrosine ammonia lyase (BO1194), wherein the genetically engineered Bacteroides ovatus is deficient in the production of p-coumaric acid, relative to the same Bacteroides ovatus that is not genetically engineered.